H2020Индивидуална стипендия2018–2020

ClinGen-PsychTx · Identifying Clinical, Demographic, and Genomic Risk Factors for Treatment-Resistant Psychiatric Disorders

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2018-04-01 → 2020-03-31
Финансиране от ЕС: 185 857 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Клиничните, демографските и генетичните фактори при шизофренията определят дали пациентът няма да реагира на стандартно лечение, например заради пол, възраст или специфичен ген. Това помага за по-бързото определяне на подходящ терапевтичен план и намаляване на страданията на болните.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Identifying Clinical, Demographic, and Genomic Risk Factors for Treatment-Resistant Psychiatric Disorders

Severe mental health disorders like schizophrenia have an enormous impact on quality of life. Up to 40% of people with schizophrenia will not respond to drug treatments. These individuals have high rates of death and can be in the hospital for very long periods of time. We need more information about the following with respect to schizophrenia treatment: are there certain factors (for example, gender, age or genetics) that contribute to not responding to treatment? To answer this question, we studied individuals with schizophrenia. In these individuals, we will look for factors that are linked with not responding to treatment. An example of a potential finding might be that people with schizophrenia who are female, of an older age, or have a certain genetic marker, may be more likely to not respond to treatment. This information can be used to develop tests that will help identify people at risk of not responding to a treatment before it is ever given, in order to tailor more aggressive (or different) treatment plans. Successful completion of this proposal will highly impact our understanding of treatments in mental health, and could reduce health care costs and most importantly, reduce the suffering in individuals with these disorders. There are millions of Europeans with a mental health disorder and a high proportion of them will not respond to treatment. If we can figure out earlier that someone will not respond to a treatment, we can give them a better or different treatment sooner.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Identifying factors contributing to treatment-resistance in psychiatric disorders could uncover shared aetiology or used to develop predictive tests to identify patients at risk of poor outcomes. Severe psychiatric disorders–here schizophrenia, bipolar disorder, major depressive disorder, and anorexia nervosa–have an enormous impact on morbidity. Up to 60% have poor outcomes despite adequate treatment. Those with treatment-resistant psychiatric disorders have high rates of mortality, higher health care costs, and are hospitalized longer. Further knowledge on how clinical, demographic, and genomic factors effect treatment-resistance in psychiatry is urgently needed. To date, I am unaware of any systematic assessment of genetic, clinical, and demographic factors associated with treatment-resistance across the 4 previously mentioned disorders simultaneously. Previous genomic studies investigating these disorders evaluated treatment-resistance for one disorder, were limited by small sample sizes, and did not consider a range of risk factors. First, I will investigate whether clinical and demographic factors are associated with treatment-resistant psychiatric disorders using Swedish National register data and whether they differ between disorders (N=20K). Second, I will examine whether different forms of genetic variation are associated with treatment-resistance, using existing samples (N=20K) with genome-wide genotyping, copy number variant, and exome data. Here, I will uncover knowledge about how genetic variation effects treatment-resistance, including shared genetic correlation. Third, I will examine the confounding effects of genetics on clinical and demographic factors for treatment-resistance. Completion of the proposed work could highly impact our understanding of treatment-resistance in psychiatry, and has the potential to reduce morbidity, mortality, and suffering in individuals with these disorders.

Оригинален текст от CORDIS (на английски).

Участници

KAROLINSKA INSTITUTET · STOCKHOLMКоординаторШвеция